Register for our free email digests:
Products
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Generics Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Billionaire Mark Cuban Surprises With US Generics Venture
To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022.
Teva And Hikma Plan Long-Term Environmental Commitments
Teva has disclosed plans to focus on climate action and resilience, responsible use of natural resources and emissions, effluents and waste, as part of a long-term environmental sustainability commitment. Meanwhile, Hikma has at the same time committed “to further reducing our climate impact and improving the resilience of our business in the face of future climate change.”
Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Biosimilars Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
Innovent Expands Internationally With Indonesia Deal
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Value-Added Medicines Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Neuraxpharm Enters Japanese Market
Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.
Teva Upbeat On Risperidone Results
Following positive trial results, Teva says it is exploring options with the US FDA for filing a long-acting subcutaneous injectable version of risperidone that it is developing with MedinCell.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.